HealthTree Logo
search more_vert
App Logo
person Sign In / Create Account
Post-ASH January 22, 2022 Myeloma Round Table
Post-ASH January 22, 2022 Myeloma Round Table image
HealthTree Round Tables for Multiple Myeloma Chapter
event Jan 22, 2022 / 12:00PM - 01:30PM EST

Event Description

We will feature some interesting studies from the annual American Society of Hematology (ASH) meeting with the authors on a Myeloma Crowd Round Table (MCRT) webcast on Saturday, January 22, 2022 at noon Eastern.

Our speakers will discuss issues including precursor conditions, the myeloma microenvironment, applications of minimal residual testing (MRD), and chromosome one abnormalities.  All will be available for an extensive question-and-answer session on any issue in the second half of the 90 minute program.


Watch The Post American Society of Hematology Meeting (ASH 2021) Round Table

Myeloma Round Table: Studies from the American Society of Hematology Meeting (ASH 2021)


Audience Questions & Answers


Schedule & Agenda

Introduction and Welcome
Introduction and Welcome
Audience Questions

Speakers & Moderators

The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Read Bio
The panelist Greg Brozeit
Greg Brozeit

Greg Brozeit has been engaged in myeloma patient advocacy since 1998. He began working with the Myeloma Crowd in 2015. Prior to that, he consulted with Dr. Bart Barlogie at the University of Arkansas after working with the International Myeloma Foundation for 15 years, where he inaugurated the public policy advocacy program, patient support group outreach and IMF Europe, organizing more than 100 physician and patient education programs. He earned his BA in political science from Loyola University in New Orleans and lives in northeast Ohio.

Read Bio
The panelist Timothy Schmidt, MD
Timothy Schmidt, MD

Dr. Timothy Schmidt is a faculty member of the Division of Hematology, Medical Oncology, and Palliative Care within the Department of Medicine at the University of Wisconsin-Madison. He is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the International Myeloma Society. Dr. Schmidt also serves as a peer reviewer for clinical hematology journals and is involved in medical education for trainees, medical professionals, and patient outreach organizations. His clinical interest is in management of hematological malignancies, including the use of bone marrow transplantation and CAR-T cell therapy. In his clinic, he specializes in caring for patients with multiple myeloma and other plasma cell disorders including monoclonal gammopathies and amyloidosis. Dr. Schmidt’s research focuses on improving outcomes for patients with multiple myeloma. He is involved in the development and conduct of early phase and cooperative group clinical trials for patients with plasma cell disorders. Dr. Schmidt is interested in differentiating patterns of disease biology that lead to variable outcomes among patients with multiple myeloma. Through outcomes research and scientific collaborations with laboratory-based researchers, Dr. Schmidt hopes to translate these findings into clinical trials that aim to clarify how treatment may be tailored for individual patients to improve survival and reduce toxicity.

Read Bio
The panelist Sigrun Thorsteinsdottir, MD, PhD
Sigrun Thorsteinsdottir, MD, PhD

Dr. Thorsteinsdotter is a postdoctoral fellow from the University of Iceland currently working at the Rigshospitalet in Copenhagen, Denmark.

Read Bio
The panelist Francesco Maura, MD
Francesco Maura, MD

Dr. Maura is assistant professor and co-director of the Myeloma Genomic Lab at the Sylvester Cancer Center at the University of Miami, Florida. His research activity is focused on the genomic mechanisms and driver events involved in the pathogenesis and progression of lymphoproliferative disorders. His main focus has been on multiple myeloma and its precursors. The other area of interest is the understanding of the key mechanisms involved in cancer resistance to novel drugs, including immunotherapy.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.


Get In Touch With Us


+1 800 709 1113


Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube